DE: Agilent Chooses Delaware for $22M Investment in Biopharma Manufacturing, to Create Jobs in Newport | Trade and Industry Development

DE: Agilent Chooses Delaware for $22M Investment in Biopharma Manufacturing, to Create Jobs in Newport

Jun 29, 2023
Investment in Newport facility will support economic and job growth over next decade

Agilent Technologies Inc., a global leader in analytical instrumentation development and manufacturing and one of Delaware's largest private-sector employers, has chosen to modernize and expand its Newport, Delaware, manufacturing facility to meet growing global demand for its biopharma consumables.

Agilent plans to invest nearly $22 million to increase the capacity of its lab-based manufacturing site in Newport, leasing 12,000 square feet adjacent to its existing facility and fitting out 9,900 square feet as lab space with new infrastructure, equipment and instrumentation. Over half of the remaining square footage will become a warehouse, storage and shipping/receiving area, and the balance will be used for offices.

This latest expansion follows another investment by Agilent last year to its Wilmington-area Little Falls R&D labs. Agilent employs 18,000 people worldwide, including more than 950 in Delaware. The Newport site employs 110 workers, and the expansion is expected to create additional new jobs over the next 10 years.

“Delaware has a strong manufacturing history, and this latest investment by Agilent Technologies confirms the company’s commitment to innovating in the First State,” said Governor John Carney. “We are pleased Agilent will be expanding and bringing more good-paying jobs to the state’s strong science, technology and biopharmaceutical sectors.”

The Newport facility, one of several Agilent manufacturing sites across the United States, produces liquid chromatography columns used for chemical and biochemical analysis, drug discovery, environmental control and analytical chemistry. Growing worldwide demand for these analytical consumables led the company to review its U.S. facilities to determine the best opportunity to grow production capacity. Agilent’s decision to invest in its Newport site in New Castle County reflects confidence in Delaware’s dynamic business environment and the large pool of regional talent.

“Agilent’s latest expansion is proof that New Castle County is a great place to create and grow your business,” said New Castle County Executive Matt Meyer. “It’s become well known that we have the resources and the talent to continue to be a leader in the chemical and biopharma industry.”

Delaware Prosperity Partnership has been engaged with Agilent as the company explored growth possibilities in Delaware. Today, DPP supported Agilent’s request to the Council on Development Finance for a Delaware Graduated Lab Space Grant of up to $693,000 from the Delaware Strategic Fund. Distribution of grants from the Delaware Strategic Fund are dependent on the company meeting commitments as outlined to the CDF, which reviewed and approved Agilent’s request.

“Agilent has been operating in Delaware for more than 20 years, and we are pleased to continue investing in our manufacturing and R&D facilities in the First State,” said Henrik Ancher-Jensen, Agilent’s Order Fulfillment and Supply Chain president. “We are honored to be part of this dynamic community that supports innovation and growth and attracts top talent.”